Lifecycle Management Trends In China Show The Need To Get Ready For Fewer, Better Generics
This article was originally published in PharmAsia News
Executive Summary
In China, multinational pharmaceutical companies are not so worried about the patent cliff, as many off-patent products enjoy premium pricing and high-growth rates even when dozens of generics exist. But how long will the party last?